Remove Contract Manufacturing Remove DNA Remove Life Science Remove Protein
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40
article thumbnail

Pfizer to Slash COVID-19 Vaccine Manufacturing Time by Almost 50 Percent

XTalks

The increased production aims will be achieved through both improved manufacturing efficiency and increasing build capacity. The drugmaker is targeting various steps in the manufacturing process, beginning right at the DNA stage, which is required as the template from which the mRNA for the SARS-CoV-2 spike protein in the vaccine is made.

article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The Skills Demand Survey Report presents a lack of graduate life sciences apprenticeship programmes as a key barrier.